1. Tolvaptan reduces the required amount of albumin infusion in patients with decompensated cirrhosis with uncontrolled ascites : a multicenter retrospective propensity score-matched cohort study
   Y Suzuki et al, 2021, Acta Gastro Enterologica Belgica CrossRef
2. Prediction factors of tolvaptan effectiveness in patients with refractory ascites complicated with hepatocellular carcinoma
   Michitaka Imai et al, 2021, European Journal of Gastroenterology & Hepatology CrossRef
3. Predictors of tolvaptan short‐term response in patients with refractory ascites: A meta‐analysis
   Ioannis Bellos et al, 2020, Journal of Gastroenterology and Hepatology CrossRef
4. Clinical implications with tolvaptan on monitored bioimpedance-defined fluid status in patients with cirrhotic ascites: an observational study
   Shunsuke Shiba et al, 2020, BMC Gastroenterology CrossRef
5. Increased serum C‐reactive protein and decreased urinary aquaporin 2 levels are predictive of the efficacy of tolvaptan in patients with liver cirrhosis
   Masato Nakai et al, 2018, Hepatology Research CrossRef
6. Tolvaptan therapy of Chinese cirrhotic patients with ascites after insufficient diuretic routine medication responses: a phase III clinical trial
   Jieting Tang et al, 2020, BMC Gastroenterology CrossRef
7. Response to tolvaptan and its effect on prognosis in cirrhotic patients with ascites
   Tomomi Kogiso et al, 2017, Hepatology Research CrossRef
8. Predictors of the Response to Tolvaptan Therapy and Its Effect on Prognosis in Cirrhotic Patients with Ascites
   Tomomi Kogiso et al, 2017, Ascites - Physiopathology, Treatment, Complications and Prognosis CrossRef